National Sleep Foundation Statement on FDA Approval of Suvorexant

Home >> Media Center >> Media Center/Press Release >> National Sleep Foundation Statement on FDA Approval of Suvorexant
Date:
Wednesday, August 13, 2014

WASHINGTON, D.C.  (August 13, 2014) – On August 13, 2014, the U.S. Food and Drug Administration (FDA), approved Merck’s new prescription sleep aid, suvorexant (brand name Belsomra).  

The following statement may be attributed to the National Sleep Foundation (NSF):

The National Sleep Foundation is encouraged by the introduction of a new generation sleep aid treatment. Millions of Americans suffer from insomnia and may benefit from a new pharmaceutical sleep aid with fewer side effects.

This drug features a promising new mechanism of action. This is the result of scientific research that provided new insight into how chemicals in the brain impact sleep and wakefulness. This is an exciting time in sleep research; we look forward to more exciting innovations in the future. 

For additional information, please view the National Sleep Foundation’s position statement on insomnia

About the National Sleep Foundation

The National Sleep Foundation is dedicated to improving health and well-being through sleep education and advocacy. It is well-known for its annual Sleep in America® poll, Sleep Awareness Week® and Drowsy Driving Prevention Week®. The Foundation is a charitable, educational and scientific not-for-profit organization located in Washington, DC. Its membership includes researchers and clinicians focused on sleep medicine, health professionals, patients, families affected by drowsy driving and more than 900 healthcare facilities. www.sleepfoundation.org.

 

###